Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

Journal of Hepatology

Volumn 67, Issue 1, 2017, Pages 65-71

  Cabibbo, Giuseppe ^a   Petta, Salvatore ^a   Barbara, Marco ^a   Attardo, Simona ^a   Bucci, Laura ^b   Farinati, Fabio ^c   Giannini, Edoardo G ^d   Negrini, Giulia ^e   Ciccarese, Francesca ^f   Rapaccini, Gian Lodovico ^g   Di Marco, Maria ^h   Caturelli, Eugenio ⁱ   Zoli, Marco ^j   Borzio, Franco ^k   Sacco, Rodolfo ^l   Virdone, Roberto ^m   Marra, Fabio ⁿ   Mega, Andrea ^o   Morisco, Filomena ^p   Benvegnù, Luisa ^q   Gasbarrini, Antonio ^r   Svegliati Baroni, Gianluca ^s   Foschi, Francesco Giuseppe ^t   Olivani, Andrea ^u   Masotto, Alberto ^o   Nardone, Gerardo ^v   Colecchia, Antonio ^b   Persico, Marcello ^w   Craxì, Antonio ^a   Trevisani, Franco ^b   Cammà, Calogero ^a   more..

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Policlinico San Marco   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h BOLOGNINI HOSPITAL   (Italy)

ⁱ BELCOLLE HOSPITAL   (Italy)

^j FATEBENEFRATELLI HOSPITAL   (Italy)

^k UNIVERSITY HOSPITAL OF PISA   (Italy)

^l Ospedali Riuniti Villa Sofia Cervello   (Italy)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ CENTRAL HOSPITAL OF BOLZANO   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p UNIVERSITY OF PADOVA   (Italy)

^q FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^r UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^s Ospedale per gli Infermi di Faenza   (Italy)

^t UNIVERSITY HOSPITAL OF PARMA   (Italy)

^u SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^v UNIVERSITY OF SALERNO   (Italy)

^w UNIVERSITY OF SALERNO   (Italy)

more..

Author keywords

Antiviral agents; Carcinoma, hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response

Indexed keywords

ABLATION THERAPY; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; EARLY CANCER; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; COMPLICATION; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS;

EID: 85015722099     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.01.033     Document Type: Article

References (33)

1. Di Marco, V., Calvaruso, V., Ferraro, D., Bavetta, M.G., Cabibbo, G., Conte, E., et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151 (2016), 130–139, e2.
2. Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., et al., ANRS CO12 CirVir group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156, e2.
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
4. Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea (NCC). KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver 9 (2015), 267–317.
5. Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150 (2016), 835–853.
6. Cabibbo, G., Petta, S., Barbàra, M., Missale, M., Virdone, R., Caturelli, E., et al., on behalf of the ITA.LI.CA study group, A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int, 2017, 10.1111/liv.13357.
7. Bruix, J., Takayama, T., Mazzaferro, V., et al., STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16 (2015), 1344–1354.
8. Cabibbo, G., Reig, M., Gadaleta-Caldarola, G., et al. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1. Future Oncol 12 (2016), 281–284.
9. Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 45 (2017), 160–168.
10. Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
11. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
12. Pol, S., Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 65 (2016), 734–740.
13. Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for Hepatocellular Carcinoma early recurrence: much ado about nothing. J Hepatol 65 (2016), 861–862.
14. Torres, H.A., Vauthey, J.N., Economides, M.P., Mahale, P., Kaseb, A., Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol 65 (2016), 862–864.
15. Nault, J.C., Colombo, M., Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol 65 (2016), 663–665.
16. Belli, L.S., Berenguer, M., Cortesi, P.A., Strazzabosco, M., Rockenschaub, S.R., Martini, S., et al., European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 65 (2016), 524–531.
17. Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al., HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.
18. Flemming, J.A., Kim, W.R., Terrault, N.A., Reduction in liver transplant wait-listing in the era of direct acting anti-viral therapy. Hepatology, 2016, 10.1002/hep.28923.
19. Therneau, T., Grambsch, P., Modeling survival data: extending the cox model. 2000, Springer-Verlag, New York.
20. Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973), 646–649.
21. Malinchoc, M., Kamath, P.S., Gordon, F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 (2000), 864–871.
22. Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., et al. Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46 (2007), 922–938.
23. Oken, M.M., Creech, R.H., Tormey, D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982), 649–655.
24. Mazzaferro, V., Regalia, E., Doci, R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996), 693–699.
25. Italian Association for the Study of the Liver (AISF) AISF Expert Panel AISF Coordinating Committee, Bolondi, L., Cillo, U., Colombo, M., Craxì, A., Farinati, F., Giannini, E.G., et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis 45 (2013), 712–723.
26. Pecorelli, A., Lenzi, B., Gramenzi, A., Garuti, F., Farinati, F., Giannini, E.G., et al., Italian Liver Cancer (ITA.LI.CA) group. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver Int, 2016, 10.1111/liv.13242.
27. Cammà, C., Di Marco, V., Orlando, A., Sandonato, L., Casaril, A., Parisi, P., et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 42 (2005), 535–540.
28. Muto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K.T., Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334 (1996), 1561–1567.
29. Imamura, H., Matsuyama, Y., Tanaka, E., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38 (2003), 200–207.
30. Mazzaferro, V., Lencioni, R., Majno, P., Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin Liver Dis 34 (2014), 415–426.
31. Wu, J.C., Huang, Y.H., Chau, G.Y., Su, C.W., Lai, C.R., Lee, P.C., et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 51 (2009), 890–897.
32. Colombo, M., Iavarone, M., Role of antiviral treatment for HCC prevention. Pract Res Clin Gastroenterol 28 (2014), 771–781.
33. Makarova-Rusher, O.V., Medina-Echeverz, J., Duffy, A.G., Greten, T.F., The yin and yang of evasion and immune activation in HCC. J Hepatol 62 (2015), 1420–1429.